Factory to move to Poland with 180 jobs at risk
Workers at a labelling factory say they have been told their site is to close and work moved to Poland.
About 180 people work at the MCC factory on the Llantarnam Industrial Estate in Cwmbran, Torfaen, making labels for food and drink products.
The site has been operating for more than 20 years, but workers have been told the company plans to close with work transferred to Poland and Romania.
In a statement MMC said there was "no immediate" change for staff and customers, and that the "proposal is subject to review".
One worker, who didn't want to be named, said the announcement came out of the blue.
"The factory goes 24/7 – it was very, very busy during lockdown, we had lots of orders, but things have declined since," they said.
"The company are saying the closure plan is a proposal but it seems set, the mood isn't hopeful.
"Workers are trying to get meetings with the Welsh government, unions and the company to see if anything can be done to save it.
"The mood is very down, people angry because they're not getting answers.
"There are not many printing jobs out there."
Almost 100 jobs to go in gelatin factory closure
Wet wipe factory closure sees 200 jobs lost
In an email to staff, MCC president Fred Noel, said: "This was a difficult but necessary decision that reflects changes in regional demands.
"We are working very closely with the local team and customers to review options and, if needed, redistribute volumes to other sites."
Nick Thomas-Symonds and Lynne Neagle, politicians who represent Torfaen, issued a joint statement saying they were "deeply concerned" by the news.
"We are in regular dialogue with officials at Torfaen Council and the Welsh government to see what can be done to prevent this closure," they said.
"With so many jobs at risk, a full and proper consultation with staff should be carried out."
The factory is part of a global company with sites around the world including the US, Europe and Australia.
With a global annual revenue of about £2.4bn the company is an industry leader in labelling, but that comes with a boardroom objective to cut costs and increase profits.
The closure of the Cwmbran site is a huge blow to the workforce and the wider community, with the letter to staff implying that its Welsh operation was no longer viable.
MCC's broader "growth strategy" involves expanding operations in Poland and Romania, and it has sites in more than 25 other countries with a workforce in excess of 12,000 people.
Attempts to boost growth in the UK will require more companies to expand their operations here, rather than shut them down.
As the Welsh government prepares to host an investment summit later this year, the impact of MCC's closure will prompt questions about the trading conditions in Wales and the support available to any new business wanting to invest.
Announcing the summit, First Minister Eluned Morgan said: "Economic growth is a top priority for me and the Welsh government will do what it can to support Welsh business and help attract even more investors into Wales."
A spokesperson for MMC said the proposal is subject to review and discussion through a collective consultation process, as required by law.
"This process is to take several months and no decisions will be made until the end of that process."
It added that the proposal is "intended to rebalance UK production based on current demands and capacity across our UK plant network".
"We are working closely with all Cwmbran customers and teammates to discuss all options, which potentially may eventually include production transfers and some job redundancies," it added.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) TAMPA, Fla., June 2, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned Phase 3 accelerated approval trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2025, in Chicago, Illinois. The Company's poster, titled "Multicenter, randomized, double-blinded, placebo-controlled trial of IFx-Hu2.0 (IFx) as adjunctive therapy with pembrolizumab (pembro) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC)" details the Company's Phase 3 accelerated approval trial design of IFx-Hu2.0, its novel innate immune agonist. The Trial in Progress poster was presented by Andrew Brohl, M.D., Medical Oncologist at Moffitt Cancer Center, and highlighted the importance of innate immune system activation in Merkel cell carcinoma patients with primary resistance to checkpoint inhibitors (CPIs). "Merkel cell carcinoma is a rare and aggressive tumor type. While checkpoint inhibitor therapy has markedly improved the outcome for patients with advanced or metastatic MCC, unfortunately for patients who don't respond to first line checkpoint inhibitor therapy the survival is poor at less than 30 months.1 Based on the results from our Phase 1 clinical trials, IFx-Hu2.0 intralesional administration has demonstrated it can activate an innate immune response, resulting in the production and activation of tumor specific B cells and T cells, to overcome the primary CPI resistance in both advanced or metastatic MCC or melanoma," stated James Bianco, M.D., President and Chief Executive Officer of TuHURA Biosciences. "We believe we have provided data requested by the FDA that addresses the requirements listed in the partial clinical hold letter to allow us to initiate our Phase 3 accelerated approval trial this month. The FDA was constructive in the trial design, which can potentially satisfy both the requirements for accelerated and regular approval without the requirements for a post approval confirmatory trial. They continue to work with us under the SPA Agreement in preparing the trial's initiation." In the Phase 1b trial of IFx-Hu2.0, MCC among patients who progressed on pembrolizumab (anti-PD-1) or avelumab (anti-PDL-1) therapy, weekly administration of IFx-Hu2.0 for up to 3 doses followed by rechallenge with anti-PD(L)-1 therapy, demonstrated an overall response rate of 63% (2CR, 5 PR) with duration of responses ranging from 6 to 33 months with 5 ongoing responses as of last follow-up in June 2024. The Company's Phase 3 accelerated approval trial of adjunctive IFx-Hu2.0, to be conducted under a SPA agreement with the U.S. FDA, will evaluate IFx-Hu2.0 (0.1 mg) as an adjunctive therapy administered weekly for three weeks concurrent to pembrolizumab (200 mg) Q3W, compared to the same pembrolizumab regimen plus placebo. The pivotal trial is expected to enroll 118 CPI-naïve patients with advanced or metastatic MCC across approximately 22 to 25 U.S. sites. Trial participants will be randomized on a 1:1 basis and receive CPI therapy for up to two years, or until disease progression or CPI related toxicities. The primary endpoint for the trial is overall response rate (ORR) with a key secondary endpoint of progression free survival (PFS). Other secondary endpoints are safety, duration of response, and overall survival. The Trial in Progress poster is available on the Scientific Publications page of TuHURA's website. 1 Kacew et al. (2020). Predictors of immunotherapy benefit in Merkel cell carcinoma. Oncotarget, 11(47), 4401–4410. About TuHURA Biosciences, Inc. TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer. TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune agonist product candidates, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. For more information, please visit and connect with TuHURA on Facebook, X, and LinkedIn. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This press release contains certain "forward-looking statements" within the meaning of, and subject to the safe harbor created by, Section 27A of the Securities Act, Section 21E of the Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," "would," "project," "plan," "expect," "goal," "seek," "future," "likely" or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA's expectations, hopes, beliefs, intentions or strategies regarding the future and include, without limitation, statements regarding TuHURA's IFx-Hu2.0 product candidate and anticipated Phase 3 trial and any developments or results in connection therewith and the anticipated regulatory pathway and timing thereof. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the SEC, which are available on the combined company's website, and at The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities. Investor Contact: Monique KosseGilmartin GroupMonique@ View original content to download multimedia: SOURCE TuHURA Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Fix system and give Wales fair funding
Wales does not get its "fair share of rail funding" and the system must be "fixed", said a former Labour minister responsible for transport. Plans for a £6.6bn Oxford-Cambridge rail line were previously classified as an England-only project, which means Wales could have been entitled to more money. But the Treasury announced there was a "publishing error" in a 2020 document and it should have been classified as an England and Wales project. Lee Waters, the Labour MS for Llanelli said the "cock-up" highlights the broader issue of how "unclear" and in need of reform the funding system is. Anger as Oxford rail line classed as England and Wales project Why does Wales not receive money from HS2? Rail plan reclassified, denying Wales funding - MP Rail in Wales is not devolved, which means funding is determined through the UK government using the Barnett formula. Speaking to BBC Radio Wales Breakfast on Monday, Waters said: "Is it cockup, is it a conspiracy? Who knows - almost always a cockup in my experience." But he said "it speaks to the broader truth" that "the system needs fixing". He said: "We have not had our fair share of funding, the formula does not work to our advantage. "It is not clear how the formula works and therefore we don't trust when things like this pop up." Waters said only a few weeks ago the Welsh government "had to dip into our own coffers" to pay for the national insurance costs, which should be covered by the UK government as per a Treasury agreement. "We need to reform the Barnett formula," Waters said. "We need to have the UK treasury acting as a UK treasury for the whole of the UK, not just for whoever happens to be in government in England at the time." He added that this is not "a party issue" because "this happened under the last government, it's happening under this government". He said it is "the government machine" which must be "changed and fixed". He said he is "confident" his London colleagues are ensuring Wales gets more funding, but is "less confident" they are trying to reform the Barnett formula. He said part of the issue is there "is not a Wales pot of money for rail, we have to fight our corner in the England and Wales pot". Waters said: "There's a UK Labour manifesto commitment to create a Wales fund for schemes so there can be transparency." But he said he is "nervous" about "wholesale devolution of rail without the extra funding", because it comes with the responsibility of repair work. He said: "You can argue we should get the extra funding, but it's back to 'do we trust the UK funding arrangements to do that?'" The UK government previously said the "error" over the Oxford-Cambridge line classification "will be amended when an update is published at the spending review". The HM Treasury has been approached for comment.
Yahoo
3 days ago
- Yahoo
WHSmith pricing 'should be illegal' after customer charged £4.19 for a Pepsi
WHSmith pricing "should be illegal", according to shocked customers. Welsh snooker legend Mark Williams recently posted a picture of a checkout screen in WHSmith, where it showed a 500ml bottle of Pepsi Max costing £4.19. Williams was at Heathrow Airport at the time. Airports across the country are slightly notorious for charging inflated prices. At the time of writing, a 500ml bottle of Pepsi Max from Tesco costs £1.59. Customers subsequently blasted the store. WHSmith pricing should be illegal in general, no clue how they get away with it — Sel (@SA1903_) June 4, 2025 One said: "WHSmith literally sold off their entire High Street business but kept travel hub shops for this very reason. It's like printing money and they don't care about the customers." Another commented: "Smiths are proper cosy cosy with all the airports, word is they mark up their prices by 50% and go halters with the airport the shops located in". Someone else replied: "I paid that in Liverpool airport a couple of weeks ago, couldn't believe my eyes". Another said: "WHSmith pricing should be illegal in general, no clue how they get away with it". Some, however, defended the pricing. Recommended reading: Jeremy Clarkson bans fan from The Farmer's Dog pub after heated argument UK government makes major driveway law change set to affect millions of homes Pest control expert issues 'incredibly sneaky' bed bug warning to all UK homes Replying to the previous post, a user commented: "It's in an airport mate". To which he responded: "Expensive in other WHSmith stores too hence why I said general". Airports tend to be expensive due to a combination of factors, including high operational costs, the captive audience they serve, and the unique challenges of operating within a confined space. These costs are then reflected in higher prices for food, beverages, retail goods, and services within the airport, as well as in airline ticket prices, which often include airport fees.